{"id":"W4379282289","doi":"10.1200/jco.2023.41.16_suppl.4132","title":"ACTION-1 phase Ib/3 trial of RYZ101 in somatostatin receptor subtype 2–expressing (SSTR2+) gastroenteropancreatic neuroendocrine tumors (GEP-NET) progressing after <sup>177</sup>Lu somatostatin analogue (SSA) therapy: Initial safety analysis.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Neuroendocrine Tumor Research Advances","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Toronto; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Neuroendocrine tumors; Nuclear medicine; Adverse effect; Internal medicine; Somatostatin receptor 2; Somatostatin receptor; Somatostatin; Radionuclide therapy; Toxicity; Pharmacokinetics; Gastroenterology; Oncology; Pharmacology; Urology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002117534,0.001559571,0.001363334,0.0004075081,0.0002710569,0.0009612215,0.0008176772,0.001036077,0.005756799],"category_scores_gemma":[0.001144605,0.0004162308,0.001501538,0.0003850185,0.0008630711,0.0009064685,0.0003411621,0.003103561,0.001158741],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001114881,"about_ca_system_score_gemma":0.001519937,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0009483921,"about_ca_topic_score_gemma":0.002657202,"domain_scores_codex":[0.9994567,0.0003059562,0.00002538602,0.00007226039,0.0000494807,0.00009023242],"domain_scores_gemma":[0.9993556,0.0001452109,0.0001568843,0.00006488174,0.00004381318,0.0002335492],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.7998851,0.03035159,0.004579112,0.001331682,0.001700519,0.0002832506,0.0002541559,0.005128668,0.04714659,0.0008744356,0.008189728,0.100275],"study_design_scores_gemma":[0.6079695,0.3710022,0.007771376,0.00007221515,0.0007565143,0.0003264659,0.0000532946,0.002335768,0.005413108,0.0005400663,0.003729485,0.00003001686],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9807976,0.003829286,0.001587107,0.0009794841,0.0001629733,0.004012608,0.003690149,0.0002854374,0.004655327],"genre_scores_gemma":[0.9734567,0.002642214,0.004273561,0.0019525,0.0001969948,0.004345571,0.008432615,0.0001044035,0.004595479],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.005756799,"threshold_uncertainty_score":0.01925838,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1190048836507754,"score_gpt":0.4956917116793705,"score_spread":0.3766868280285951,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}